FDA 483 - Frontida Biopharm, LLC - October 24, 2025

During an FDA inspection conducted from October 20-24, 2025, Frontida Biopharm, LLC, a drug manufacturer based in Aurora, IL, received an FDA Form 483. This document outlined significant observations indicating potential deviations from Current Good Manufacturing Practices (CGMP) related to the company's quality and production systems.

Key issues identified included the absence of a fully functional quality control unit with adequate responsibility and authority for approving materials, investigating production errors, managing field alert reports, and reviewing written quality procedures. Furthermore, the firm lacked formal, written procedures defining the quality unit's roles and responsibilities, particularly for its multi-site operations spanning Illinois and Pennsylvania. Deficiencies were noted in establishing clear communication pathways, testing, release, and approval authorities between sites, and in having proper controls for in-process materials transferred between facilities. Critically, quality agreements were missing, and the firm failed to ensure proper notification of stability failures between its locations.

The inspection also revealed inadequate process validation procedures, specifically failing to identify and evaluate shipping conditions for in-process drug products transferred between facilities as a critical process step. Lastly, the company did not follow its own written procedures for segregating raw materials by release status, with instances of commingled released and unreleased materials observed in the warehouse. To ensure compliance with federal regulations, Frontida Biopharm is required to thoroughly address these observations and implement effective corrective actions.